EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

Mark Lebwohl iD, Richard B Warren iD, Howard Sofen, Shinichi Imafuku, Carle Paul iD, Jacek C Szepietowski iD, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck und 3 weitere

British Journal of Dermatology · 17.04.2024 · 190 (5) · 668-679

DOI: 10.1093/bjd/ljae014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 16.01.2024. Verfasst von Mark Lebwohl und 14 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Pandemics, Psoriasis, Heterocyclic Compounds. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1 year in patients with psoriasis.

Objective

To evaluate deucravacitinib safety and efficacy over 2 years in patients participating in the phase III trials.

Methods

In the POETYK long-term extension (LTE), an ongoing phase IIIb open-label trial, adults with moderate-to-severe plaque psoriasis who completed PSO-1 or PSO-2 receive deucravacitinib 6 mg once daily. Safety was assessed via adverse events (AEs) and laboratory parameter abnormalities. Efficacy endpoints, including ≥ 75% reduction from baseline Psoriasis Area and Severity Index score (PASI 75) and static Physician’s Global Assessment (sPGA) score of 0/1 (clear/almost clear), were evaluated in patients originally randomized to deucravacitinib, patients who crossed over from placebo at week 16 and patients who achieved PASI 75 at week 24 (peak efficacy).

Results

At data cutoff (1 October 2021), 1519 patients had received at least one dose of deucravacitinib; 79.0% and 39.9% had ≥ 52 weeks and ≥ 104 weeks of total deucravacitinib exposure, respectively. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were similar at 1 year and 2 years for any AEs (229.2 vs. 154.4, respectively), serious AEs (5.7 vs. 6.1), discontinuations (4.4 vs. 2.8), deaths (0.2 vs. 0.4), serious infections (1.7 vs. 2.6), herpes zoster (0.9 vs. 0.8), major adverse cardiovascular events (0.3 vs. 0.4), venous thromboembolic events (0.2 vs. 0.1) and malignancies (1.0 vs. 0.9). EAIRs for COVID-19 infections were higher at 2 years than at 1 year (5.1 vs. 0.5) owing to the peak of the global COVID-19 pandemic occurring during the LTE. No clinically meaningful changes from baseline or trends were observed over 2 years in haematological, chemistry or lipid parameters. Clinical responses were maintained in patients who received continuous deu­cravacitinib treatment from baseline [PASI 75: week 52, 72.4%; week 112, 79.7%; sPGA 0/1: week 52, 57.9%; week 112, 61.1% (as observed)]. Responses at week 52 were also maintained in placebo crossovers and in week-24 PASI-75 responders.

Conclusions

Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PandemicsPsoriasisHeterocyclic CompoundsAdultHumansSeverity of Illness IndexTreatment OutcomeDouble-Blind Method

Substanzen

deucravacitinibHeterocyclic Compounds

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
  • NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
  • Fukuoka University Hospital, Fukuoka, Japan.
  • Toulouse University and CHU, Toulouse, France.

ORCID-Profile: Mark Lebwohl, Richard B Warren, Carle Paul, Jacek C Szepietowski, Diamant Thaçi

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Lebwohl, M., Warren, R. B., Sofen, H., Imafuku, S., Paul, C., Szepietowski, J. C., Spelman, L., Passeron, T., Vritzali, E., Napoli, A., Kisa, R. M., Buck, A., Banerjee, S., Thaçi, D., & Blauvelt, A. (2024). Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. British Journal of Dermatology, 190(5), 668-679. https://doi.org/10.1093/bjd/ljae014

Vancouver

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. British Journal of Dermatology. 2024;190(5):668-679. doi:10.1093/bjd/ljae014

BibTeX
@article{Lebwohl2024,
  author = {Lebwohl, Mark and Warren, Richard B and Sofen, Howard and Imafuku, Shinichi and Paul, Carle and Szepietowski, Jacek C and Spelman, Lynda and Passeron, Thierry and Vritzali, Eleni and Napoli, Andrew and Kisa, Renata M and Buck, Alex and Banerjee, Subhashis and Thaçi, Diamant and Blauvelt, Andrew},
  title = {Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials},
  journal = {British Journal of Dermatology},
  year = {2024},
  volume = {190},
  number = {5},
  pages = {668--679},
  doi = {10.1093/bjd/ljae014}
}
Kostenlos starten →